Apnimed director granted options for 44,477 shares

Apnimed, Inc. director William A. Jones Jr. reported derivative transactions involving stock options for 44,477 shares of common stock at an exercise price of $16.00 per share, expiring on July 29, 2036.

Accepted by SEC EDGAR 08/03/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Apnimed, Inc. director William A. Jones Jr. reported derivative transactions involving stock options for 44,477 shares of common stock at an exercise price of $16.00 per share, expiring on July 29, 2036. The options are scheduled to vest in substantially equal monthly installments over 36 months after July 30, 2026, contingent on his continued service. The filing also notes a reclassification in which each share of Class A common stock was reclassified into one share of common stock pursuant to Rule 16b-7 and Rule 16b-3, which is described as an exempt reclassification.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider JONES WILLIAM A JR

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy) F1, F2	44,477	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F2	44,477	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F2	44,477	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 88,954 contracts (Direct)

Footnotes (2)

1. F1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
2. F2. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Option Shares Granted: 44,477 shares Exercise Price: $16.00 per share Option Expiration: July 29, 2036 +1 more

4 metrics

Option Shares Granted 44,477 shares Stock options reported for William A. Jones Jr.

Exercise Price $16.00 per share Conversion or exercise price of reported stock options

Option Expiration July 29, 2036 Expiration date of the stock options

Vesting Period 36 months Monthly vesting after July 30, 2026, subject to continued service

Key Terms

Rule 16b-7, Rule 16b-3, reclassification, vest and become exercisable

4 terms

Rule 16b-7 regulatory

"reclassification exempt under Rule 16b-7 and Rule 16b-3"

A U.S. Securities and Exchange Commission safe-harbor rule that shields corporate insiders (officers, directors and large shareholders) from automatic short-swing profit claims when they buy or sell their company’s stock under a pre-approved, written plan that follows specific timing and nondiscretionary rules. For investors, the rule matters because it distinguishes routine, formula-driven insider transactions from opportunistic trades that could trigger automatic profit recoveries—think of it as an approved autopilot for insider trading that reduces legal uncertainty when the plan’s conditions are met.

Rule 16b-3 regulatory

"reclassification exempt under Rule 16b-7 and Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

reclassification financial

"each share of Class A Common Stock was reclassified into one share"

Reclassification is the formal change in how an asset, liability, security, transaction, or business activity is labeled on financial records or under rules. It matters to investors because the new label can alter reported profits, tax treatment, ownership rights or perceived risk—much like moving an item from 'personal' to 'business' use, it doesn't create value by itself but can change comparisons, taxes, and who controls outcomes.

vest and become exercisable financial

"shares subject to such option vest and become exercisable in monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apnimed (APMD) director William A. Jones Jr. report?

Director William A. Jones Jr. reported stock option grants covering 44,477 shares of Apnimed common stock at an exercise price of $16.00 per share, expiring on July 29, 2036, with vesting over 36 months after July 30, 2026.

How many Apnimed (APMD) shares are covered by the new stock options?

The reported stock options cover 44,477 shares of Apnimed common stock. These options are scheduled to vest in substantially equal monthly installments over 36 months after July 30, 2026, subject to the director’s continued service to the company.

What is the exercise price and expiration date of the Apnimed (APMD) options?

The stock options reported for Apnimed have an exercise price of $16.00 per share and an expiration date of July 29, 2036. These terms apply to the 44,477 options granted to director William A. Jones Jr.

When do the Apnimed (APMD) stock options for William A. Jones Jr. vest?

The options vest and become exercisable in substantially equal monthly installments over 36 months after July 30, 2026. Vesting is conditioned on William A. Jones Jr.’s continuous service to Apnimed on each vesting date.

What reclassification of shares did Apnimed (APMD) disclose in this Form 4?

Apnimed disclosed that each share of Class A common stock was reclassified into one share of common stock. The company states this reclassification was exempt under Rule 16b-7 and Rule 16b-3 of the securities regulations.

Were the Apnimed (APMD) insider option transactions under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not reference any Rule 10b5-1 trading plan. The reported transactions are presented without an associated pre-arranged trading plan in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES WILLIAM A JR

(Last) (First) (Middle)

APNIMED, INC.

39 JOHN F. KENNEDY STREET, 4TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apnimed, Inc. [ APMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	07/30/2026		A		44,477		(2)	07/29/2036	Class A Common Stock	44,477	$0.00	44,477	D
Stock Option (Right to Buy)	$16	08/03/2026		D(1)		44,477		(2)	07/29/2036	Class A Common Stock	44,477	$0.00	0	D
Stock Option (Right to Buy)	$16	08/03/2026		A(1)		44,477		(2)	07/29/2036	Common Stock	44,477	$0.00	44,477	D

Explanation of Responses:

1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

2. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/Kevin R. Lind, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)